medigraphic.com
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán

2012, Number 3

<< Back Next >>

Rev Invest Clin 2012; 64 (3)

Participation of damage-associated molecular patterns in conventional treatment of cancer

Rojo-León V, Aguilar-Cázares D, Prado-García H, Carlos-Reyes Á, López-González JS

Language: Spanish
References: 75
Page: 275-283
PDF size: 256.40 Kb.


ABSTRACT

Cells of the innate immune system are involved in discriminating between the innocuous cell death (apoptosis) which occurs in tissues during homeostasis, and the cell death associated to tissue damage (necrosis). Recently, a new variant of apoptosis termed immunogenic apoptosis has been described. In cancer, this type of cell death has acquired great relevance. In vitro and in vivo experimental models support that radiotherapy and some chemotherapeutic drugs induce the immunogenic apoptosis of malignant cells. Dying cells express at cytoplasmic membrane or release several nuclear or intracytoplasmic molecules termed “danger signals” or damage associated molecular patterns (DAMPs). DAMPs alert the organism and play a role inducing an efficient anti-tumor immune response. In this review, the importance of cell death by immunogenic apoptosis, the cytotoxic drugs that induce this type of cell death, the biologic role of some DAMPs and their participation in the activation of the antitumor immune response, in particular in the phagocytic cell, are indicated. The goal of this information should impact in improving the participation of the immune system in the recognition and efficient elimination of the residual tumor cells and to overcome the evasion mechanisms of tumor cells. This knowledge should lead to a better control of the growth of tumors with a concomitant reduction in the tumor recurrence. Also, an increase in the survival of the cancer patients or probably their definitive cure could be reached in the future.


REFERENCES

  1. Erwig LP, Henson PM. Immunological consequences of apoptotic cell phagocytosis. Am J Pathol 2007; 171: 2-8.

  2. Krysko DV, Vandenabeele P. Clearance of dead cells: Mechanisms, immune responses and implication in the development of diseases. Apoptosis 2010; 15: 995-7.

  3. Green DR, Ferguson T, Zitvogel L, Kroemer G. Immunogenic and tolerogenic cell death. Nat Rev Immunol 2009; 9: 353-63.

  4. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell 2006; 124: 783-801.

  5. Jeannin P, Jaillon S, Delneste Y. Pattern recognition receptors in the immune response against dying cells. Curr Opin Immunol 2008; 20: 530-7.

  6. Chen GY, Nunez G. Sterile inflammation: Sensing and reacting to damage. Nat Rev Immunol 2010; 10: 826-37.

  7. Apetoh L, Tesniere A, Ghiringhelli F, Kroemer G, Zitvogel L. Molecular interactions between dying tumor cells and the innate immune system determine the efficacy of conventional anticancer therapies. Cancer Res 2008; 68: 4026-30.

  8. Bianchi ME. DAMPs, PAMPs and alarmins: All we need to know about danger. J Leukoc Biol 2007; 81: 1-5.

  9. Garg AD, Nowis D, Golab J, Vandenabeele P, et al. Immunogenic cell death, DAMPs and anticancer therapeutics: An emerging amalgamation. Biochim Biophys Act 2010; 1805: 53-71.

  10. Zitvogel L, Kepp O, Kroemer G. Decoding cell death signals in inflammation and immunity. Cell 2010; 140: 798-804.

  11. Kono H, Rock KL. How dying cells alert the immune system to danger. Nat Rev Immunol 2008; 8: 279-89.

  12. Matzinger P. Tolerance, danger, and the extended family. Annu Rev Immunol 1994; 12: 991-1045.

  13. Matzinger P. The danger model: A renewed sense of self. Science 2002; 296: 301-5.

  14. Yang D, Tewary P, De la Rosa G, Wei F, Oppenheim JJ. The alarmin functions of high-mobility group proteins. Biochim Biophys Act 2010; 1799: 157-63.

  15. Aderem A, Underhill DM. Mechanisms of phagocytosis in macrophages. Annu Rev Immunol 1999; 17: 593-623.

  16. Poon IK, Hulett MD, Parish CR. Molecular mechanisms of late apoptotic/necrotic cell clearance. Cell Death Differ 2010; 17: 381-97.

  17. Tesniere A, Panaretakis T, Kepp O, Apetoh L, et al. Molecular characteristics of immunogenic cancer cell death. Cell Death Differ 2008; 15: 3-12.

  18. Anisimov VN. Carcinogenesis and aging 20 years after: Escaping horizon. Mech Ageing Dev 2009; 130: 105-21.

  19. Ponder BA. Cancer genetics. Nature 2001; 411: 336-41.

  20. Smyth MJ, Godfrey DI, Trapani JA. A fresh look at tumor immunosurveillance and immunotherapy. Nat Immunol 2001; 2: 293-9.

  21. Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 2004; 21: 137-48.

  22. Vieweg J, Jackson A. Modulation of antitumor responses by dendritic cells. Springer Semin Immunopathol 2005; 26: 329-41.

  23. Palucka AK, Ueno H, Fay JW, Banchereau J. Taming cancer by inducing immunity via dendritic cells. Immunol Rev 2007; 220: 129-50.

  24. Bromley SK, Burack WR, Johnson KG, Somersalo K, et al. The immunological synapse. Annu Rev Immunol 2001; 19: 375-96.

  25. Marincola FM, Wang E, Herlyn M, Seliger B, Ferrone S. Tumors as elusive targets of T-cell-based active immunotherapy. Trends Immunol 2003; 24: 335-42.

  26. June CH. Principles of adoptive T cell cancer therapy. J Clin Invest 2007; 117: 1204-12.

  27. Dhodapkar MV, Dhodapkar KM, Palucka AK. Interactions of tumor cells with dendritic cells: Balancing immunity and tolerance. Cell Death Differ 2008; 15: 39-50.

  28. Zitvogel L, Tesniere A, Kroemer G. Cancer despite immunosurveillance: Immunoselection and immunosubversion. Nat Rev Immunol 2006; 6: 715-27.

  29. Rabinovich GA, Gabrilovich D, Sotomayor EM. Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol 2007; 25: 267-96.

  30. Vermeulen K, Van Bockstaele DR, Berneman ZN. Apoptosis: Mechanisms and relevance in cancer. Ann Hematol 2005; 84: 627-39.

  31. De Vita VT Jr CE. Principles of medical oncology. In: De Vita VT Jr HS, Rosenberg SA (ed.). Cancer: Principles and practice of oncology. 8th. Ed. Philadelphia, Pa: Lippincott-Williams and Wilkins; 2008, p. 337-45.

  32. Lawrence TS TR, Giaccia A. Principles of radiation oncology. In: De Vita VT Jr HS, Rosenberg SA (ed.). Cancer: Principles and practice of oncology. 8th. Ed. Philadelphia, Pa: Lippincott- Williams and Wilkins; 2008, p. 307-10.

  33. Zitvogel L, Apetoh L, Ghiringhelli F, Kroemer G. Immunological aspects of cancer chemotherapy. Nat Rev Immunol 2008; 8: 59-73.

  34. Haynes NM, van der Most RG, Lake RA, Smyth MJ. Immunogenic anti-cancer chemotherapy as an emerging concept. Curr Opin Immunol 2008; 20: 545-57.

  35. Zitvogel L, Apetoh L, Ghiringhelli F, Andre F, et al. The anticancer immune response: Indispensable for therapeutic success? J Clin Invest 2008; 118: 1991-2001.

  36. Casares N, Pequignot MO, Tesniere A, Ghiringhelli F, et al. Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J Exp Med 2005; 202: 1691-701.

  37. Haskill JS. Adriamycin-activated macrophages as tumor growth inhibitors. Cancer Res 1981; 41: 3852-6.

  38. Ho RL, Maccubbin D, Zaleskis G, Krawczyk C, et al. Development of a safe and effective adriamycin plus Interleukin 2 therapy against both adriamycin-sensitive and -resistant lymphomas. Oncol Res 1993; 5: 373-81.

  39. Zaleskis G, Ho RL, Diegelman P, Maccubbin D, et al. Intracellular doxorubicin kinetics in lymphoma cells and lymphocytes infiltrating the tumor area in vivo: A flow cytometric study. Oncol Res 1994; 6: 183-94.

  40. Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 2007; 13: 1050-9.

  41. Apetoh L, Mignot G, Panaretakis T, Kroemer G, Zitvogel L. Immunogenicity of anthracyclines: Moving towards more personalized medicine. Trends Mol Med 2008; 14: 141-51.

  42. Tesniere A, Schlemmer F, Boige V, Kepp O, et al. Immunogenic death of colon cancer cells treated with oxaliplatin. Oncogene 2010; 29: 482-91.

  43. Nowak AK, Lake RA, Marzo AL, Scott B, et al. Induction of tumor cell apoptosis in vivo increases tumor antigen cross-presentation, cross-priming rather than cross-tolerizing host tumor- specific CD8 T cells. J Immunol 2003; 170: 4905-13.

  44. Taieb J, Chaput N, Menard C, Apetoh L, et al. A novel dendritic cell subset involved in tumor immunosurveillance. Nat Med 2006; 12: 214-9.

  45. Kepp O, Galluzzi L, Martins I, Schlemmer F, et al. Molecular determinants of immunogenic cell death elicited by anticancer chemotherapy. Cancer Metastasis Rev 2011; 30: 61-9.

  46. Gardai SJ, McPhillips KA, Frasch SC, Janssen WJ, et al. Cellsurface calreticulin initiates clearance of viable or apoptotic cells through trans-activation of LPR on the phagocyte. Cell 2005; 123: 321-34.

  47. Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 2007; 13: 54-61.

  48. Panaretakis T, Kepp O, Brockmeier U, Tesniere A, et al. Mechanisms of pre-apoptotic calreticulin exposure in immunogenic cell death. EMBO J 2009; 28: 578-90.

  49. Binder RJ, Srivastava PK. Peptides chaperoned by heat-shock proteins are a necessary and sufficient source of antigen in the cross-priming of CD8+ T cells. Nat Immunol 2005; 6: 593-9.

  50. Somersan S, Larsson M, Fonteneau JF, Basu S, et al. Primary tumor tissue lysates are enriched in heat shock proteins and induce the maturation of human dendritic cells. J Immunol 2001; 167: 4844-52.

  51. Reeves R. Nuclear functions of the HMG proteins. Biochim Biophys Act 2010; 1799: 3-14.

  52. Andersson U, Erlandsson-Harris H, Yang H, Tracey KJ. HMGB1 as a DNA-binding cytokine. J Leukoc Biol 2002; 72: 1084-91.

  53. Lotze MT, Tracey KJ. High-mobility group box 1 protein (HMGB1): Nuclear weapon in the immune arsenal. Nat Rev Immunol 2005; 5: 331-42.

  54. Bianchi ME, Manfredi AA. High-mobility group box 1 (HMGB1) protein at the crossroads between innate and adaptive immunity. Immunol Rev 2007; 220: 35-46.

  55. Dumitriu IE, Baruah P, Manfredi AA, Bianchi ME, Rovere- Querini P. HMGB1: Guiding immunity from within. Trends Immunol 2005; 26: 381-7.

  56. Rovere-Querini P, Capobianco A, Scaffidi P, Valentinis B, et al. HMGB1 is an endogenous immune adjuvant released by necrotic cells. EMBO Rep 2004; 5: 825-30.

  57. Bonaldi T, Talamo F, Scaffidi P, Ferrera D, et al. Monocytic cells hyperacetylate chromatin protein HMGB1 to redirect it towards secretion. EMBO J 2003; 22: 5551-60.

  58. Gardella S, Andrei C, Ferrera D, Lotti LV, et al. The nuclear protein HMGB1 is secreted by monocytes via a non-classical, vesicle-mediated secretory pathway. EMBO Rep 2002; 3: 995- 1001.

  59. Dumitriu IE, Bianchi ME, Bacci M, Manfredi AA, Rovere- Querini P. The secretion of HMGB1 is required for the migration of maturing dendritic cells. J Leukoc Biol 2007; 81: 84-91.

  60. Yang D, Chen Q, Yang H, Tracey KJ, et al. High mobility group box-1 protein induces the migration and activation of human dendritic cells and acts as an alarmin. J Leukoc Biol 2007; 81: 59-66.

  61. Andersson U, Wang H, Palmblad K, Aveberger AC, et al. High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes. J Exp Med 2000; 192: 565-70.

  62. Rouhiainen A, Kuja-Panula J, Wilkman E, Pakkanen J, et al. Regulation of monocyte migration by amphoterin (HMGB1). Blood 2004; 104: 1174-82.

  63. Apetoh L, Ghiringhelli F, Tesniere A, Criollo A, et al. The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy. Immunol Rev 2007; 220: 47-59.

  64. Yang H, Hreggvidsdottir HS, Palmblad K, Wang H, et al. A critical cysteine is required for HMGB1 binding to toll-like receptor 4 and activation of macrophage cytokine release. Proc Natl Acad Sci USA 2010; 107: 11942-7.

  65. Messmer D, Yang H, Telusma G, Knoll F, et al. High mobility group box protein 1: An endogenous signal for dendritic cell maturation and Th1 polarization. J Immunol 2004; 173: 307-13.

  66. Shi Y, Galusha SA, Rock KL. Cutting edge: Elimination of an endogenous adjuvant reduces the activation of CD8 T lymphocytes to transplanted cells and in an autoimmune diabetes model. J Immunol 2006; 176: 3905-08.

  67. Shi Y, Evans JE, Rock KL. Molecular identification of a danger signal that alerts the immune system to dying cells. Nature 2003; 425: 516-21.

  68. Chen CJ, Shi Y, Hearn A, Fitzgerald K, et al. Myd88-dependent IL-1 receptor signaling is essential for gouty inflammation stimulated by monosodium urate crystals. J Clin Invest 2006; 116: 2262-71.

  69. Martinon F, Petrilli V, Mayor A, Tardivel A, Tschopp J. Goutassociated uric acid crystals activate the NALP3 inflammasome. Nature 2006; 440: 237-41.

  70. Hu DE, Moore AM, Thomsen LL, Brindle KM. Uric acid promotes tumor immune rejection. Cancer Res 2004; 64: 5059-62.

  71. Ghiringhelli F, Apetoh L, Tesniere A, Aymeric L, et al. Activation of the NLRP3 inflammasome in dendritic cells induces IL- 1beta-dependent adaptive immunity against tumors. Nat Med 2009; 15: 1170-8.

  72. Aymeric L, Apetoh L, Ghiringhelli F, Tesniere A, et al. Tumor cell death and ATP release prime dendritic cells and efficient anticancer immunity. Cancer Res 2010; 70: 855-8.

  73. Martins I, Tesniere A, Kepp O, Michaud M, et al. Chemotherapy induces ATP release from tumor cells. Cell Cycle 2009; 8: 3723-8.

  74. Tesniere A, Apetoh L, Ghiringhelli F, Joza N, et al. Immunogenic cancer cell death: A key-lock paradigm. Curr Opin Immunol 2008; 20: 504-11.

  75. Kepp O, Tesniere A, Schlemmer F, Michaud M, et al. Immunogenic cell death modalities and their impact on cancer treatment. Apoptosis 2009; 14: 364-75.




2020     |     www.medigraphic.com